Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease.
Florian KrackhardtMatthias WaliszewskiViktor KočkaPetr ToušekBronislav JanekMartin HudecFernando LozanoKoldobika Garcia-San RomanBruno Garcia Del BlancoJosepa MauriTay Mok HeangTae Hoon AhnMyung Ho JeongDenny HerbergerVjekoslav TomulicGilles LevyLaurent SebaghJérôme RischnerMichel PansieriPublished in: Cardiovascular drugs and therapy (2020)
Within the framework of a post hoc analysis based on a real-world, large cohort study, there were no differences in the combined endpoint of major adverse cardiac events (MACE), bleeding and thrombotic events for clopidogrel and ticagrelor in stable CAD or ACS patients. Despite the recommendation for clopidogrel by the European Society of Cardiology (ESC), real-world ticagrelor use was observed in subgroups of stable CAD patients that ought to be explored in future trials.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- coronary artery disease
- end stage renal disease
- ejection fraction
- st segment elevation myocardial infarction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- emergency department
- type diabetes
- atrial fibrillation
- cardiovascular events
- left ventricular
- transcatheter aortic valve replacement
- aortic valve